Shanghai Fosun Pharmaceutical (Group) Co Ltd (08HH.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 09:05PM CEST
| Previous close | 1.5500 |
| Open | 1.5900 |
| Bid | 1.3760 x N/A |
| Ask | 1.7950 x N/A |
| Day's range | 1.5830 - 1.5900 |
| 52-week range | 1.3750 - 2.6150 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
© 2024 Yahoo. All rights reserved.